Pharma BD Deal Intelligence
Merck's $250M option-exercise on mRNA-4157/V940 looked prescient: weeks later KEYNOTE-942 showed the Moderna combo with KEYTRUDA cut recurrence or death risk 44% in resected high-risk melanoma, validating the 50/50 bet before data even dropped.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Merck has exercised its option to co-develop and co-commercialize Moderna's individualized neoantigen cancer vaccine mRNA-4157/V940, paying $250 million for a…
During the third quarter of 2022, Merck exercised its option pursuant to the existing collaboration and license agreement for mRNA-4157, our investigational…
Five-year KEYNOTE-942 data for intismeran autogene plus KEYTRUDA presented at the 2026 ASCO Annual Meeting, confirming durable recurrence-free and…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Merck exercised its option (under the 2016 Merck/Moderna collaboration) to jointly develop and commercialize Moderna's individualized neoantigen therapy mRNA-4157/V940 (now INN: intismeran autogene), paying Moderna a $250M option-exercise payment. Following the exercise the companies share future development costs and profits 50/50 worldwide; the $250M payment was confirmed in Moderna's Q3 2022 10-Q, so the option exercise is complete. The decision came weeks before the Phase 2b KEYNOTE-942 readout, which in December 2022 met its primary endpoint of recurrence-free survival in combination with KEYTRUDA in resected high-risk stage III/IV melanoma. The program subsequently advanced to pivotal Phase 3 (INTerpath-001 in adjuvant melanoma, NCT05933577, now fully enrolled; INTerpath NSCLC studies enrolling), with eight Phase 2/3 trials underway across melanoma, NSCLC, bladder cancer and renal cell carcinoma. Five-year KEYNOTE-942 data (announced Jan 20 2026 and presented at the 2026 ASCO Annual Meeting) showed sustained RFS benefit (HR 0.510; 49% reduction in risk of recurrence or death) versus KEYTRUDA alone.
98K US cases/yr · $8.0B Global melanoma therapeutics market (2022) · ~7,990 U.S. annual melanoma deaths
Cutaneous melanoma is the fifth most common cancer in the U.S. with approximately 97,600 new invasive cases and 7,990 deaths projected annually. Stage III resected melanoma carries a 5-year overall survival of 40-78% depending on substage, with stage IIIC/D representing the highest-risk adjuvant population. Adjuvant standard of care is anti-PD-1 monotherapy (Keytruda or Opdivo), which improves recurrence-free survival but leaves substantial residual recurrence risk. Approximately 30-50% of resected stage III patients still recur within 5 years on adjuvant pembrolizumab, defining the unmet need that personalized cancer vaccines target. mRNA-4157/V940 is an individualized neoantigen therapy: tumor and normal tissue are sequenced, up to 34 patient-specific neoantigens are encoded into an mRNA vaccine, and the construct is administered with pembrolizumab. The KEYNOTE-942 Phase 2b randomized trial in resected stage IIIB-IV melanoma met its primary endpoint of recurrence-free survival, reducing the risk of recurrence or death by 44% (HR 0.56, p=0.0266) versus pembrolizumab alone, the first positive randomized adjuvant individualized cancer vaccine readout in oncology.
Adjuvant high-risk melanoma is dominated by anti-PD-1 monotherapy across multiple stage groupings. Keytruda (pembrolizumab, Merck) is FDA-approved adjuvant in stage IIB/IIC/III based on KEYNOTE-054 and KEYNOTE-716 readouts. Opdivo (nivolumab, Bristol Myers Squibb) carries adjuvant labels in resected stage III/IV based on CheckMate-238. Targeted-therapy adjuvant for BRAF V600-mutant disease combines Tafinlar+Mekinist (dabrafenib + trametinib, Novartis) per COMBI-AD. Adjuvant intensification is the active battleground, with personalized neoantigen vaccines as the leading entrant. mRNA-4157/V940 (Merck/Moderna individualized mRNA) is the most advanced and currently in the Phase 3 INTERIM-V940-001 program covering melanoma and adjuvant NSCLC. Competitor cancer vaccine assets include autogene cevumeran (BNT122, BioNTech/Genentech) in pancreatic cancer Phase 2, NEO-PV-01 (Genocea/BioNTech, discontinued program), and personalized peptide vaccines from Immatics, Gritstone Bio, and Nouscom. Combination immunotherapy backbones include Yervoy (ipilimumab, BMS) plus or minus Opdivo for resected stage III, and Opdualag (nivolumab + relatlimab anti-LAG-3, BMS) extending to adjuvant trials. The Merck-Moderna option exercise locks in 50/50 economics for what would be the first individualized adjuvant cancer vaccine to deliver positive randomized data.
mRNA-4157/V940 plus KEYTRUDA reduced risk of recurrence or death by 44% (HR 0.56, p=0.0266) vs KEYTRUDA alone in resected high-risk stage III/IV melanoma.
Five-year follow-up: HR 0.510, 49% reduction in risk of recurrence or death vs KEYTRUDA alone. mRNA-4157/V940 assigned INN intismeran autogene; INTerpath-001 Phase 3 melanoma fully enrolled; eight Phase 2/3 trials across melanoma, NSCLC, bladder and RCC.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Moderna Inc. (mRNA-4157/V940 option exercise) (this deal) | 2022 | $250M | — |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2022 deals · Merck & Co. Inc. deals · Oncology deals